CFDB - Cystic Fibrosis DataBase

at least one term
all terms
All subcategories » congress abstract

Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment of upper airways

primary studies  congress abstract

Details
  • 2019
  • Taccetti G

The use of an alternate side lying positioning strategy during inhalation therapy does not prolong nebulisation time in adults with Cystic Fibrosis: a randomised crossover trial

primary studies  congress abstract

Details
  • 2018
  • Dentice RL

A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1)

primary studies  congress abstract

Details
  • 2018
  • Loebinger M

Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomized, controlled, crossover trial

primary studies  congress abstract

Details
  • 2018
  • Radtke T

MOOD AND PHYSICAL ACTIVITY OF CYSTIC FIBROSIS PATIENTS IN INPATIENT EXERGAMING PROGRAM

primary studies  congress abstract

Details
  • 2018
  • Bessette HC

Effects of tezacaftor/ivacaftor treatment in patients with cystic fibrosis and F508DEL/ F508DEL-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial

primary studies  congress abstract

Details
  • 2018
  • Yang Y

Effect of a wearable fitness tracker on exercise tolerance for adults with cystic fibrosis: a pilot randomized clinical trial

primary studies  congress abstract

Details
  • 2018
  • Bishay LC

An observational study of ivacaftor in patients with cystic fibrosis and selected non-G551D gating mutations in UK, Italy and Netherlands: healthcare resource utilization from the first interim analysis of the vocal study

primary studies  congress abstract

Details
  • 2018
  • Castellani C

Effects of GLP-1 and GIP on insulin secretion in glucose intolerant, pancreatic insufficient cystic fibrosis

primary studies  congress abstract

Details
  • 2018
  • Eiel JN

A single dose of a novel nebulised pde3/4 inhibitor rpl554 increased fev1 in patients with cystic fibrosis and demonstrated a reproducible pharmacokinetic profile

primary studies  congress abstract

Details
  • 2018
  • Eneje OJ